NIOX GroupCSSPF 77 PB Ratio is 3.69 as of Jun. 24, 2026, which is 89% above its 10-year median of 1.95. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 787 Medical Devices & Instruments companies, NIOX Group ranks worse than 70.52% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), NIOX Group's share price is $0.79965. NIOX Group's Book Value per Share for the quarter that ended in Dec. 2025 was $0.22. Hence, NIOX Group's PB Ratio of today is 3.69.
Good Sign:
NIOX Group PLC stock PB Ratio (=3.56) is close to 1-year low of 3.41.
The historical rank and industry rank for NIOX Group's PB Ratio or its related term are showing as below:
CSSPF'
s PB Ratio Range Over the Past 10 Years
Min: 0.43 Med: 1.95 Max: 5.07
Current: 3.56
During the past 13 years, NIOX Group's highest PB Ratio was 5.07. The lowest was 0.43. And the median was 1.95.
CSSPF's PB Ratio is ranked worse than 70.52% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.04
vs CSSPF: 3.56
During the past 12 months, NIOX Group's average Book Value Per Share Growth Rate was 8.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -6.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -0.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -19.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of NIOX Group was 114.50% per year. The lowest was -38.80% per year. And the median was -5.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
NIOX Group PB Ratio Related Terms
NIOX Group PB Ratio Historical Data
* Premium members only.
The historical data trend for NIOX Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where NIOX Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
NIOX Group's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
NIOX Group (CSSPF) has a PB Ratio of 3.69 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NIOX Group and its competitors. This is 89% above median its historical median of 1.95. Over the past decade, NIOX Group's PB Ratio has ranged from 0.43 to 5.07. According to the industry distribution chart, NIOX Group ranks #555 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 70.5%.
Is NIOX Group's PB Ratio too high?
NIOX Group's current PB Ratio of 3.69 is 89% above median its 10-year median of 1.95. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 5.07. The Medical Devices & Instruments industry median PB Ratio is 2.04. NIOX Group's value of 3.69 is 80.9% above this industry median. Based on the distribution chart, NIOX Group ranks #555 out of 787 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #555 out of 787 companies for PB Ratio. This places NIOX Group in the lower half of its industry. The industry median PB Ratio is 2.04. NIOX Group's value of 3.69 is 80.9% above this benchmark. Historically, NIOX Group's own PB Ratio has ranged from 0.43 to 5.07 over the past decade. While the company's 10-year median is 1.95 vs. the industry median of 2.04, NIOX Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.04, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current PB Ratio of 3.69 is 80.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current PB Ratio is 3.69, which is 89% above median its own 10-year median of 1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.80 — trading 33.9% below its estimated fair value. The current PB Ratio is 3.69, which is 89% above median its 10-year median of 1.95 and 80.9% above the Medical Devices & Instruments industry median of 2.04. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For NIOX Group (CSSPF), the current PB Ratio is 3.69 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.80 is trading 33.9% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
PB Ratio: 3.69 (89% above median its 10-year median of 1.95)
GF Value™: $1.21 vs. price of $0.80 (33.9% below fair value)
Industry Position: 80.9% above the Medical Devices & Instruments median (#555 of 787)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
